Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

8. Dezember 2015 aktualisiert von: Translational Research in Oncology

A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer

This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

170

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Deutschland
      • Berlin, Deutschland, 12200
        • Charite Campus Benjamin Franklin
      • Berlin, Deutschland, 13353
        • University Hospital Charité
      • Bonn, Deutschland, 53105
        • Universitat Bonn
      • Erlangen, Deutschland, 91054
        • Universitätsklinikum Erlangen
      • Hamburg, Deutschland, 20246
        • Universitätsklinikum Hamburg Eppendorf
      • Homburg, Deutschland, 66421
        • Universitätsklinikum des Saarlandes
      • Kassel, Deutschland, 34125
        • Klinikum Kassel
      • Munich, Deutschland, 80637
        • Rotkreuzkrankenhaus Munchen
      • Tubingen, Deutschland, 72076
        • Universitats Frauenklinik Tubingen
  • Frankreich
      • La Roche Sur Yon, Frankreich, 85925
        • Centre Hospitalier Departemental Les Oudairies
      • Lyon, Frankreich, 69373
        • Centre Leon Berard
      • Neuilly Sur Seine, Frankreich, 92200
        • Clinique Hartmann
      • Paris, Frankreich, 75005
        • Institut Curie
  • Irland
      • Dublin, Irland
        • St Jame's Hospital
      • Waterford, Irland
        • Waterford Regional Hospital
  • Israel
      • Kfar-Saba, Israel, 44281
        • Meir Medical Center
      • Ramat Gan, Israel, 52621
        • Sheba Medical Center
      • Rehovot, Israel, 76100
        • Kaplan Medical Center
      • Tel Aviv, Israel, 64239
        • Sourasky Medical Center
      • Zrifin, Israel, 70300
        • Asaf Harofe MC
  • Kanada
    • Alberta
      • Edmonton, Alberta, Kanada, T6G1Z2
        • Cross Cancer Institute
    • Ontario
      • London, Ontario, Kanada, N6A4L6
        • London Health Science Center
    • Quebec
      • Montreal, Quebec, Kanada, H3T1E2
        • Jewish General Hospital
      • Montreal, Quebec, Kanada, H2L4M1
        • Chum Hopital Notre Dame
  • Spanien
      • Barcelona, Spanien, 08036
        • Hospital Clinic I Provincial
      • Guadalajara, Spanien, 19002
        • Hospital Universitario de Guadalajara
      • La Laguna, Spanien, 38320
        • Hospital Universitario de Tenerife
      • Madrid, Spanien, 28041
        • Hospital U 12 de Octubre
      • Sevilla, Spanien, 341071
        • Hospital Universitario Virgen Macarena de Sevilla
  • Vereinigte Staaten
    • California
      • Alhambra, California, Vereinigte Staaten, 91801
        • Central Hematology Oncology Medical Group Inc.
      • Burbank, California, Vereinigte Staaten, 91505
        • Providence Saint Joseph Medical Center
      • Fullerton, California, Vereinigte Staaten, 92835
        • St Jude Heritage Healthcare
      • La Verne, California, Vereinigte Staaten, 91750
        • Wilshire Oncology Medical Group Inc
      • Los Angeles, California, Vereinigte Staaten, 90033
        • University of Southern California
      • Los Angeles, California, Vereinigte Staaten, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Vereinigte Staaten, 90095-1678
        • UCLA
      • Northridge, California, Vereinigte Staaten, 91325
        • North Valley Hematology/Oncology Medical Group
      • Oxnard, California, Vereinigte Staaten, 93030
        • Ventura County Hematology-Oncology Specialists
      • San Francisco, California, Vereinigte Staaten, 94115
        • University of California San Francisco
      • santa Maria, California, Vereinigte Staaten, 93454
        • Central Coast Medical Oncology Corporation
    • Connecticut
      • New Haven, Connecticut, Vereinigte Staaten, 06510
        • Yale University School of Medicine
    • Florida
      • Hollywood, Florida, Vereinigte Staaten, 33021
        • Memorial Cancer Institute
      • Orlando, Florida, Vereinigte Staaten, 32804
        • Florida Hospital Cancer Institute
      • Tampa, Florida, Vereinigte Staaten, 33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Winship Cancer Institute Emory University School of Medicine
    • Louisiana
      • Metairie, Louisiana, Vereinigte Staaten, 70006
        • Hematology And Oncology Specialists, Llc
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Mayo Clinic
    • Nevada
      • Henderson, Nevada, Vereinigte Staaten, 89052
        • Comprehensive Cancer Centers of Nevada
    • North Carolina
      • Asheville, North Carolina, Vereinigte Staaten, 28806
        • Hope A Women's Cancer Center
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27104
        • Wake Forest University Baptist Medical Center
    • Ohio
      • Toledo, Ohio, Vereinigte Staaten, 43614
        • University of Toledo
      • Toledo, Ohio, Vereinigte Staaten, 43606
        • The Toledo Hospital
  • Vereinigtes Königreich
      • Leeds, Vereinigtes Königreich, LS97TF
        • Saint James's University Hospital
      • London, Vereinigtes Königreich, W1T4TJ
        • University College London
      • Northwood, Vereinigtes Königreich, HA62RN
        • Mount Vernon Cancer Centre

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Histologically-confirmed optimally debulked (< 1 cm) FIGO stage III or stage IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
  • Patients should have undergone surgical debulking, by a surgeon experienced in the management of ovarian cancer, with the aim of maximal surgical cytoreduction. All patients must be optimally debulked as defined as having no residual tumor of greater than 1 cm in the post surgical setting.
  • Patients with stage IV disease will be eligible if a positive pleural cytology is the only extra peritoneal disease.
  • Paraffin block (or 10 - 20 unstained slides) and fresh frozen surgical/biopsy specimens of the primary tumor are required at baseline.
  • No prior systemic treatment in the primary disease treatment setting.
  • Female ≥ 18 years of age or legal age.
  • ECOG performance status ≤ 2.
  • Adequate organ and bone marrow function

  • Non diabetic patients or Type 1 or 2 Diabetic Patients:

    • Diabetes must be controlled with HgbA1c < 8% and fasting blood glucose level <160 mg/dL.

  • Patient must be willing and able to comply with scheduled visits, and all study procedures.
  • Informed consent obtained.
  • Patients should be able to commence systemic therapy within 6 weeks of cytoreductive surgery.
  • Life expectancy > 12 weeks.
  • Adequate coagulation parameters (within 14 days prior to randomization), International Normalized Ratio (INR) ≤1.5; Activated Prothrombin Time (APTT) ≤ 1.5 x ULN

Exclusion Criteria:

  • Non-epithelial ovarian cancer, including malignant mixed Mullerian tumors.
  • Borderline tumors (tumors of low malignant potential).
  • Planned intraperitoneal cytotoxic chemotherapy.
  • Prior systemic anticancer therapy for ovarian cancer.
  • Any previous radiotherapy to the abdomen or pelvis.
  • Patients with synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless ALL of the following criteria for describing the endometrial carcinoma are met: Stage ≤ Ib, no more than superficial myometrial invasion, no lymphovascular invasion, not poorly differentiated (i.e., not Grade 3 or papillary serous or clear cell).
  • Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri or curatively treated DCIS/LCIS, or non-melanoma or in situ melanoma skin cancer.
  • Prior treatment with a humanized monoclonal antibody anticancer therapeutic.
  • Prior treatment with investigational treatment targeted to IGF axis including, but not limited to, CP 751,871, IM-A12, RO4858696.
  • Previous exposure to AMG 479.
  • Anticipation of a need for a major surgical procedure or radiation therapy during the study.
  • History of hypersensitivity to recombinant proteins.
  • Treatment with radiotherapy, surgery, or an investigational agent within 4 weeks of randomization.
  • Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, grade > 2 peripheral neuropathy, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.
  • History of brain metastases, spinal cord compression, or carcinomatous meningitis.
  • Patient of child-bearing potential is pregnant (eg, positive human chorionic gonadotropin test) or is breast feeding.
  • Patient of child-bearing potential is not willing to use adequate contraceptive precautions.
  • Known active infection, or on antiretroviral therapy for HIV disease.
  • Known positive test for chronic hepatitis B or C infection.
  • Any other underlying physical or mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
  • Refusal or inability to give informed consent to participate in the study.
  • Other severe acute or chronic medical or psychiatric condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the patient's safety, inhibit protocol participation, or interfere with interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: A
Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.
Arzneimittel: AMG 479 Placebo
Matching placebo administered Day 1 of each 21 day cycle.
Experimental: B
AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.
Arzneimittel: AMG 479
Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression Free Survival (PFS): Time From Randomization Until Date of Progression or Death.
Zeitfenster: Radiological tumor assessment: every 12(+/- 1) weeks for 3 years after randomization + CA 125: day 1 of each cycle

A patient may have been declared to have progressive disease on the basis of radiological measuremt of tumor lesions assessmt or CA125 evaluation (tumor measuremts taking precedence).Radiological progression was defined as per the RECIST guidelines (Therasse et al, JNCI2000) as at least 20% increase in the sum of the longest diameters of target lesions(ref the smallest sum of the longest diam recorded since the treatmt started or since the appearance of at least 1 new lesion).Serum CA125 progression was defined, according to the 2005 GCIG def: pts with:

  • Elevated CA125 pretreatmt and normalization of CA125 has to show evidence of CA125≥ 2 times the upper normal limit on 2 occasions at least 1 wk apart OR
  • Elevated CA125 pretreatmt which never normalized must show evidence of CA125≥ 2 times the nadir value on 2 occasions at least 1 wk apart OR
  • CA125 in the normal range pretreatmt had to show evidence of CA125 ≥ 2 times the upper normal limit on 2 occasions at least 1 wk apart
Radiological tumor assessment: every 12(+/- 1) weeks for 3 years after randomization + CA 125: day 1 of each cycle

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time To Progression (TTP): Interval From the Date of Randomization to the Date of Disease Progression
Zeitfenster: Radiological tumor assessment: every 12 (+/- 1) weeks for 3 years after randomization + CA125: day 1 of each cycle

A patient may have been declared to have progressive disease on the basis of radiological measuremt of tumor lesions assessmt or CA125 evaluation (tumor measuremts taking precedence).Radiological progression was defined as per the RECIST guidelines (Therasse et al, JNCI2000) as at least 20% increase in the sum of the longest diameters of target lesions(ref the smallest sum of the longest diam recorded since the treatmt started or since the appearance of at least 1 new lesion).Serum CA125 progression was defined, according to the 2005 GCIG def: pts with:

  • Elevated CA125 pretreatmt and normalization of CA125 has to show evidence of CA125≥ 2 times the upper normal limit on 2 occasions at least 1 wk apart OR
  • Elevated CA125 pretreatmt which never normalized must show evidence of CA125≥ 2 times the nadir value on 2 occasions at least 1 wk apart OR
  • CA125 in the normal range pretreatmt had to show evidence of CA125 ≥ 2 times the upper normal limit on 2 occasions at least 1 wk apart
Radiological tumor assessment: every 12 (+/- 1) weeks for 3 years after randomization + CA125: day 1 of each cycle
Overall Survival (OS)
Zeitfenster: Day 1 of each cycle up to 4 years after randomization
Interval between the date from randomization to death from any cause whichever came first.
Day 1 of each cycle up to 4 years after randomization

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Translational Research in Oncology

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Januar 2009

Primärer Abschluss (Tatsächlich)

1. September 2013

Studienabschluss (Tatsächlich)

1. November 2014

Studienanmeldedaten

Zuerst eingereicht

17. Juli 2008

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. Juli 2008

Zuerst gepostet (Schätzen)

18. Juli 2008

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

12. Januar 2016

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

8. Dezember 2015

Zuletzt verifiziert

1. Dezember 2015

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • TRIO 014

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren